[go: up one dir, main page]

WO2005065074A3 - La protection de tissus et de cellules contre les effets cytotoxique d'un rayonnement ionisant par des inhibiteurs abl - Google Patents

La protection de tissus et de cellules contre les effets cytotoxique d'un rayonnement ionisant par des inhibiteurs abl Download PDF

Info

Publication number
WO2005065074A3
WO2005065074A3 PCT/US2004/028654 US2004028654W WO2005065074A3 WO 2005065074 A3 WO2005065074 A3 WO 2005065074A3 US 2004028654 W US2004028654 W US 2004028654W WO 2005065074 A3 WO2005065074 A3 WO 2005065074A3
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compounds
ionizing radiation
cells
radiation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/028654
Other languages
English (en)
Other versions
WO2005065074A2 (fr
Inventor
E Premkumar Reddy
M V Ramana Reddy
Stephen C Cosenza
Kiranmai Gumireddy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Temple Univ School of Medicine
Original Assignee
Temple Univ School of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Temple Univ School of Medicine filed Critical Temple Univ School of Medicine
Publication of WO2005065074A2 publication Critical patent/WO2005065074A2/fr
Publication of WO2005065074A3 publication Critical patent/WO2005065074A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un pré-traitement à l'aide d'un ou de plusieurs composés représentés par la formule (I), telle que décrite ici, destiné à protéger les cellules normales des effets secondaires toxiques d'un rayonnement ionisant. L'administration d'un ou de plusieurs composés radioprotecteurs, représentés par la formule (I), à un patient avant une radiothérapie anticancéreuse permet de réduire les effets secondaires cytotoxiques du rayonnement sur les cellules normales. L'effet radioprotecteur d'un ou de plusieurs composés représentés par la formule (I) permet d'augmenter en toute sécurité le dosage des rayonnements anticancéreux. L'augmentation de la toxicité suite à une exposition aux rayonnements par inadvertance peut également être réduite grâce à l'administration d'un ou de plusieurs composés représentés par la formule (I).
PCT/US2004/028654 2003-09-09 2004-09-02 La protection de tissus et de cellules contre les effets cytotoxique d'un rayonnement ionisant par des inhibiteurs abl Ceased WO2005065074A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50178303P 2003-09-09 2003-09-09
US60/501,783 2003-09-09

Publications (2)

Publication Number Publication Date
WO2005065074A2 WO2005065074A2 (fr) 2005-07-21
WO2005065074A3 true WO2005065074A3 (fr) 2006-02-23

Family

ID=34748731

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/028654 Ceased WO2005065074A2 (fr) 2003-09-09 2004-09-02 La protection de tissus et de cellules contre les effets cytotoxique d'un rayonnement ionisant par des inhibiteurs abl

Country Status (1)

Country Link
WO (1) WO2005065074A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11851426B2 (en) 2019-10-11 2023-12-26 Incyte Corporation Bicyclic amines as CDK2 inhibitors

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006104668A2 (fr) * 2005-03-11 2006-10-05 Temple University - Of The Commonwealth System Of Higher Education Compositions et procedes de traitement de maladies profilerantes
PL1902029T5 (pl) * 2005-07-01 2022-08-29 Wyeth Llc Krystaliczne postacie 4-[(2,4-dichloro-5-metoksyfenylo)amino]-6-metoksy-7-[3(-4-metylo-1-piperazynylo)propoksy]-3-chinolino-karbonitrylu i sposoby ich wytwarzania
KR20090101905A (ko) * 2006-12-22 2009-09-29 노파르티스 아게 인돌-４-일-피리미디닐-일-아민 유도체 및 사이클린 의존성 키나제 억제제로서의 그의 용도
US20100048597A1 (en) * 2006-12-22 2010-02-25 Novartis Ag Organic Compounds and Their Uses
TWI433677B (zh) 2007-06-04 2014-04-11 Avila Therapeutics Inc 雜環化合物及其用途
EA023535B9 (ru) * 2010-03-26 2016-11-30 Онконова Терапьютикс, Инк. Композиция водного радиопротекторного фармацевтического раствора и способ предотвращения, снижения или исключения эффектов ионизирующей радиации
CN102731474B (zh) * 2011-04-13 2014-12-03 石药集团中奇制药技术（石家庄）有限公司 一种伊马替尼的制备方法
CN103772391A (zh) * 2012-10-23 2014-05-07 杨子娇 一类治疗房角狭窄的化合物及其用途
EP3054936B1 (fr) 2013-10-10 2023-10-18 Eastern Virginia Medical School Dérivés de 4-((2-hydroxy-3-méthoxybenzyl)amino)benzènesulfonamide comme inhibiteur de la 12-lipoxygénase
CN105384686B (zh) * 2014-09-04 2019-07-26 连云港润众制药有限公司 一种博舒替尼结晶方法
CN105085398A (zh) * 2015-09-06 2015-11-25 合肥华方医药科技有限公司 一种博舒替尼异构体杂质的制备方法
CN105503748A (zh) * 2015-12-31 2016-04-20 哈药集团技术中心 一种吉非替尼的制备方法
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020168197A1 (fr) 2019-02-15 2020-08-20 Incyte Corporation Composés de pyrrolo[2,3-d]pyrimidinone en tant qu'inhibiteurs de cdk2
WO2020180959A1 (fr) 2019-03-05 2020-09-10 Incyte Corporation Composés de pyrazolyl pyrimidinylamine en tant qu'inhibiteurs de cdk2
WO2020205560A1 (fr) 2019-03-29 2020-10-08 Incyte Corporation Composés sulfonylamides utilisés comme inhibiteurs de la cdk2
WO2020223469A1 (fr) 2019-05-01 2020-11-05 Incyte Corporation Dérivés de n-(1-(méthylsulfonyl)pipéridin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine et composés apparentés utilisés en tant qu'inhibiteurs de kinase 2 dépendante des cyclines (cdk2) pour le traitement du cancer
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
CA3150681A1 (fr) 2019-08-14 2021-02-18 Incyte Corporation Composes imidazolyl-pyrimidinylamines utilises comme inhibiteurs de la cdk2
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CLIN CANCER RES., vol. 9, no. 6, 2 June 2003 (2003-06-02), pages 1957 - 1971 *
CLIN. CANCER RES., vol. 8, no. 10, 1 October 2002 (2002-10-01), pages 3250 - 3258 *
DATABASE EMBASE [online] BIANCO C. ET AL: "Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa)", XP002994720, accession no. STN Database accession no. 2002365991 *
DATABASE EMBASE WACHSBERGER P. ET AL: "Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: Exploring mechanisms of interaction", XP002994721 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11851426B2 (en) 2019-10-11 2023-12-26 Incyte Corporation Bicyclic amines as CDK2 inhibitors

Also Published As

Publication number Publication date
WO2005065074A2 (fr) 2005-07-21

Similar Documents

Publication Publication Date Title
WO2005044181A3 (fr) Protection de tissus et de cellules des effets cytotoxiques d'un rayonnement ionisant par des inhibiteurs abl
WO2005065074A3 (fr) La protection de tissus et de cellules contre les effets cytotoxique d'un rayonnement ionisant par des inhibiteurs abl
EP1370253A4 (fr) Methode de protection des cellules et des tissus contre la toxicite du rayonnement ionisant par des arylsulfones $g(a),$g(b) non satures
GB2433070A (en) Porphyrin derivatives and their use in photon activation therapy
MXPA05007352A (es) Compuestos triciclicos inhibidores de proteina quinasa para mejorar la eficacia de agentes antineoplasicos y terapia de radiacion.
GEP20125469B (en) Inhibitors of akt activity
WO2006020722A3 (fr) Compositions pharmaceutiques de beta-lapachone et d'analogues de beta-lapachone possedant un potentiel de ciblage de tumeur ameliore
MX2007009649A (es) Derivados de meleimida, composiciones farmaceuticas y metodos para el tratamiento del cancer.
MXPA05013142A (es) Compuestos de piridinio [1,2-a]pirimidin-4-ona como agentes anticancer.
TNSN07341A1 (en) Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
BRPI0415953B8 (pt) formulação de dosagem de liberação controlada e conjunto de formas de dosagem de liberação controlada
MX2010002735A (es) Envase de titulacion para neramexano y su uso en el tratamiento de un trastorno del oido interno.
WO2005004808A3 (fr) Composes tetracycliques utilises comme inhibiteurs de c-met
ATE439134T1 (de) Medikament zum schutz in der radiotherapie
WO2001074376A3 (fr) Utilisation des inhibiteurs de cathepsine dans le traitement du cancer
WO2009129510A3 (fr) Préparations à base de sulindac dans un matériau biodégradable
TW200718689A (en) 2-Amino-quinazolin-5-ones
WO2005039554A3 (fr) Utilisation therapeutique de la methionine pour le traitement ou la prevention de la mucosite
WO2009019708A3 (fr) Compositions pharmaceutiques et procédés pour le traitement du cancer
WO2006020403A3 (fr) 3-bromo-2-oxopropionate de propyle et ses derives utilises comme nouveaux agents anticancereux
WO2009045053A3 (fr) Sensibilisant du cancer comprenant un acide chlorigénique
TW200509909A (en) Use of organic compounds
AU2002249103A1 (en) Succinimide and maleimide derivatives and their use as topoisomerase ii catalytic inhibitors
ECSP078015A (es) 4-anilino-3-quinolinocarbonitrilos para el tratamiento de cáncer
WO2007032010A3 (fr) Utilisation de composes tellures pour la protection contre le rayonnement ultralviolet

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase